AtkinsRéalis Group (ATRL) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Achieved strong Q2 results with 15% revenue growth to $2.7B, driven by nuclear and Linxon; nuclear revenue up 59% to $567M.
Record total backlog of $21B, with nuclear backlog up 223% year-over-year to $5.6B, and engineering services backlog at $13B, up 6%.
Closed acquisition of David Evans Enterprises for $404M, expanding US presence; completed sale of Highway 407 ETR stake, generating $2.6B in proceeds and a $2.57B gain.
Over 9M shares repurchased, strengthening capital returns; balance sheet now net cash positive, enabling focus on organic and inorganic growth.
Upgraded to investment grade credit ratings and maintained a robust, leverage-neutral position.
Financial highlights
Total IFRS revenues up 15% year-over-year to $2.7B; segment-adjusted EBIT up 18% to $246M.
Adjusted EPS from PS and PM rose 59% to $0.78 per diluted share.
IFRS net income surged to $2.32B, mainly from a $2.57B gain on the Highway 407 ETR sale.
Free cash flow for the quarter was -$163M, with operating cash flow expected to exceed $300M for full year 2025.
Cash and cash equivalents at $953M as of June 30, 2025.
Outlook and guidance
Raised 2025 nuclear revenue outlook to $2.0B–$2.1B, with 11%–13% segment-adjusted EBIT to revenue ratio.
Lowered 2025 organic revenue growth outlook for engineering services regions to mid-single digits due to USLA and EMEA softness.
Segment-adjusted EBITDA to net revenue ratio for engineering services regions guided at 16%–17%.
All other 2025 financial outlook metrics maintained; net cash from operations projected to exceed $300M.
Management continues to evaluate impacts of upcoming IFRS standards and amendments.
Latest events from AtkinsRéalis Group
- Record revenue, earnings, and backlog in 2025 set the stage for continued growth in 2026.ATRL
Q4 202527 Feb 2026 - Targeting >8% organic growth, margin expansion, and nuclear leadership with disciplined capital allocation.ATRL
Investor Day 20243 Feb 2026 - Record backlog, double-digit growth, and upgraded nuclear outlook highlight Q2 2024.ATRL
Q2 20241 Feb 2026 - Q3 2024 delivered record Nuclear backlog, margin gains, and robust cash flow generation.ATRL
Q3 202414 Jan 2026 - Record 2024 revenue, backlog, and $2.8B asset sale set up growth and margin gains for 2025.ATRL
Q4 20242 Dec 2025 - Record backlog and surging Nuclear growth drive raised outlook and strong Q1 2025 results.ATRL
Q1 202519 Nov 2025 - Q3 2025 saw double-digit revenue and EPS growth, record backlog, and raised Nuclear guidance.ATRL
Q3 202513 Nov 2025